Table 4.
Summary of treatment-emergent adverse events that occurred with ipragliflozin treatment at a frequency of at least 2% (by MedDRA preferred term) in the pooled ipragliflozin comparative studies (excluding hypoglycaemiaa)
| Adverse event characteristics | Ipragliflozin 50 mg (N = 1209) n (%) |
Placebo (N = 796) n (%) |
|---|---|---|
| Nasopharyngitis | 199 (16.5) | 117 (14.7) |
| Pollakiuria | 65 (5.4) | 12 (1.5) |
| Constipation | 37 (3.1) | 12 (1.5) |
| Thirst | 31 (2.6) | 6 (0.8) |
Participants treated with at least one dose of study drug
MedDRA Medical Dictionary for Regulatory Activities
aHypoglycaemia events are excluded from this summary owing to the effects of other glucose-lowering medications